Advanced search    

Search: authors:"I. Holen"

7 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo

Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post-menopausal patients show anti-tumour benefit with ZOL whereas pre-menopausal patients do not. Here we have developed in vivo models of spontaneous ER+ve breast cancer metastasis to bone and investigated the effects of ZOL and oestrogen...

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

20 30 31 P.-F. Conte 11 12 31 B. Ejlertsen 11 13 14 31 J. Bergh 11 15 31 M. Kaufmann 11 16 31 I. Holen 11 18 28 31 0 Interdisciplinary Breast Cancer Center HELIOS Klinikum Berlin-Buch Germany

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

62 Clinical Oncology Department, University of Nottingham, University Hospitals, City Hospital Campus , Nottingham , UK 63 PD Ottewell, DV Lefley, RE Coleman, I Holen Clinical Oncology, Department of

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid

62 Clinical Oncology Department, University of Nottingham, University Hospitals, City Hospital Campus , Nottingham , UK 63 PD Ottewell, DV Lefley, RE Coleman, I Holen Clinical Oncology, Department of

Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro

I Holen, H Neville-Webbe, RE Coleman DU39, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK Breast Cancer Research 2006, 8(Suppl 2):S12 (DOI 10.1186/bcr1555

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo

I Holen, H Neville-Webbe, RE Coleman DU39, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK Breast Cancer Research 2006, 8(Suppl 2):S12 (DOI 10.1186/bcr1555